Adults 20 to 75, any sex, with Dyslipidemia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Part B: Change in LDL-C in Serum at Week 12Primary· Baseline to week 12
Part B: Change from baseline in LDL-C at week 12. Results are based on Mixed Model Repeated Measures (MMRM) analysis on the log-transformed change from baseline. Log-transformed change from baseline is calculated as the visit value in log minus the baseline value in log. The results from the model are then back transformed. Note: log(week 12 data) - log(baseline data) = log(week12/baseline), which is a ratio
Group
Value
95% CI
Part B:AZD8233 50mg
0.198
0.167 – 0.235
Part B:AZD8233 15mg
0.458
0.388 – 0.541
Part B:Placebo
0.953
0.806 – 1.128
Part B: Percentage Change From Baseline in LDL-C in Serum at Week 12Secondary· Measurement at baseline and week 12
Percentage change from baseline to week 12 in Low-density Lipoprotein Cholesterol (LDL-C) in serum
Group
Value
95% CI
Part B:AZD8233 50mg
-77.13
-83.67 – -70.59
Part B:AZD8233 15mg
-52.48
-58.85 – -46.11
Part B:Placebo
-3.24
-9.68 – 3.19
Part B: Change in PCSK9 in Plasma at Week 12Secondary· Baseline to week 12
Part B: Change from baseline in PCSK9 in plasma at week 12. Results are based on Mixed Model Repeated Measures (MMRM) analysis on the log-transformed change from baseline. Log-transformed change from baseline is calculated as the visit value in log minus the baseline value in log. The results from the model are then back transformed. Note: log(week 12 data) - log(baseline data) = log(week12/baseline), which is a ratio
Group
Value
95% CI
Part B:AZD8233 50mg
0.066
0.055 – 0.079
Part B:AZD8233 15mg
0.296
0.248 – 0.352
Part B:Placebo
0.874
0.731 – 1.045
Part B: Percentage Change From Baseline in PCSK9 in Plasma at Week 12Secondary· Measurement at baseline and week 12
Percentage change from baseline to week 12 in proprotein convertase subtilisin/kexin type-9 (PCSK9) in plasma
Group
Value
95% CI
Part B:AZD8233 50mg
-92.91
-99.00 – -86.82
Part B:AZD8233 15mg
-65.07
-71.03 – -59.12
Part B:Placebo
-11.92
-18.01 – -5.82
Part A & Part C: AUC (0-24) of AZD8233Secondary· Day 1 and Day 57
Area Under the plasma concentration time curve from time 0 to time 24 hours
Day 1
Group
Value
95% CI
Part A:AZD8233 90mg
5736
± 53.55
Part C: AZD8233 60mg
3906
± 26.56
Day 57
Group
Value
95% CI
Part A:AZD8233 90mg
5377
± 50.57
Part C: AZD8233 60mg
3493
± 32.47
Part A & Part C: Cmax of AZD8233Secondary· Day 1 and Day 57
Maximum plasma concentration
Day 1
Group
Value
95% CI
Part A:AZD8233 90mg
1525
± 62.11
Part C: AZD8233 60mg
830.8
± 23.90
Day 57
Group
Value
95% CI
Part A:AZD8233 90mg
1271
± 70.63
Part C: AZD8233 60mg
781.2
± 50.34
Part A & Part C: t1/2 of AZD8233Secondary· Day 1 and Day 57
Terminal half-life
Day 1
Group
Value
95% CI
Part A:AZD8233 90mg
3.459
± 45.69
Part C: AZD8233 60mg
2.751
± 35.94
Day 57
Group
Value
95% CI
Part A:AZD8233 90mg
2.848
± 44.73
Part C: AZD8233 60mg
2.527
± 28.36
Part A & Part C: CL/F (L/h) of AZD8233Secondary· Day 1 and Day 57
Apparent plasma clearance
Day 1
Group
Value
95% CI
Part A:AZD8233 90mg
15.58
± 52.84
Part C: AZD8233 60mg
15.31
± 26.36
Day 57
Group
Value
95% CI
Part A:AZD8233 90mg
16.62
± 50.44
Part C: AZD8233 60mg
17.14
± 32.25
Part A & Part C: Vz/F (L)Secondary· Day 1 and Day 57
Apparent Volume of distribution during the terminal phase
Day 1
Group
Value
95% CI
Part A:AZD8233 90mg
77.74
± 106.7
Part C: AZD8233 60mg
60.77
± 56.66
Day 57
Group
Value
95% CI
Part A:AZD8233 90mg
68.30
± 58.04
Part C: AZD8233 60mg
62.49
± 56.80
Adverse events — posted to ClinicalTrials.gov
Time frame: From date of first dose, throughout treatment period and including follow-up period, 24 weeks for Parts A, B and C..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of Part A , Part B and Part C. Part A is designed as a randomized, single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study. Part B is designed as a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study. Part C is designed as a randomized , single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
· NA
· recruiting
NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients
· NA
· active not recruiting
NCT06919302 — The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.
· NA
· recruiting
NCT07162441 — A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and
· Phase 1
· recruiting
NCT07043166 — Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
· recruiting
Other AstraZeneca trials
Trials by the same sponsor.
NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
· not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential
· not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
· NA
· not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec
· Phase 4
· not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04823611.